The CYCLONE-2 study aimed to evaluate the efficacy of Verzenio in combination with Zytiga (abiraterone) but did not meet its primary endpoint. This development underscores the challenges pharmaceutical companies face in finding effective treatments for mCRPC, a form of the disease that progresses despite hormonal therapy aimed at reducing testosterone levels.
Eli Lilly’s commitment to combatting various forms of cancer remains undeterred, as evidenced by its recent $1.4 billion acquisition of Point Biopharma. However, the acquisition’s lead drug has faced setbacks, particularly when compared to Novartis’ Pluvicto. Similarly, Johnson & Johnson has entered the fray with a $2 billion investment in Ambrx Biopharma’s antibody-drug conjugates, highlighting the competitive landscape of prostate cancer treatment research.
This announcement marks the second recent setback for Verzenio, following its failure to meet overall survival goals in an advanced breast cancer trial and a previous Phase II prostate cancer study as a monotherapy. Despite these challenges, Verzenio has excelled in the breast cancer market, generating $3.86 billion in full-year sales for Lilly in 2023, marking a 56% increase from the previous year.
Eli Lilly also noted that another Phase III trial is ongoing to assess Verzenio’s effectiveness in hormone-sensitive prostate cancer, reflecting the company’s continued exploration of the drug’s potential across different cancer types. Additionally, the company disclosed the removal of a Phase I RET inhibitor from its development pipeline, signaling a strategic refocusing on its most promising therapeutic candidates.
The failure of the CYCLONE-2 trial in mCRPC represents a significant disappointment for Eli Lilly, especially considering Verzenio’s robust performance in the breast cancer domain. The drug, which received its first-in-class FDA approval in 2021 for certain patients with HR-positive, HER2-negative early breast cancer post-surgery, had previously shown promise in early trial phases. Unfortunately, the anticipated benefits did not extend to a broader patient population in the subsequent Phase III study, despite maintaining a consistent safety profile.
As the pharmaceutical industry continues to navigate the complex landscape of cancer treatment, Eli Lilly’s experiences underscore the unpredictability of drug development and the importance of ongoing research to address unmet medical needs.
https://www.fiercepharma.com/pharma/eli-lillys-verzenio-fails-prostate-cancer-test-possible-novartis-showdown-nears

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
